evidence table

Cacao Flavanol Cognitive Performance Randomized Trial Evidence Table

Name: Cacao Flavanol Cognitive Performance Randomized Trial Evidence Table
Creator: Migaku
License: https://creativecommons.org/licenses/by/4.0/

Structured evidence table for Cacao Flavanol Cognitive Performance Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.

topic	claim	evidence level	citation	source
Cacao Flavanol Cognitive Performance Randomized Trial	6 2,7–9 10 11 12 13 Although amyloid-beta and tau hypotheses have been the primary hypotheses in the underlying pathogenesis of AD, emerging evidence suggests that amyloidegenesis can be exacerbated by oxidative stress, leading to AD development and progression [].	3	Zainuddin Muhammad-Safuan (2026)	Oxidative stress biomarkers and flavonoids in Alzheimer's disease: current clinical evidence and therapeutic perspectives
Cacao Flavanol Cognitive Performance Randomized Trial	Growing evidence suggests that oxidative stress and impairment of innate antioxidative defence may precede the pathological features of AD and clinical manifestations [,].	3	Zainuddin Muhammad-Safuan (2026)	Oxidative stress biomarkers and flavonoids in Alzheimer's disease: current clinical evidence and therapeutic perspectives
Cacao Flavanol Cognitive Performance Randomized Trial	Therefore, this review aims to highlight evidence of oxidative biomarkers across different specimens, including post-mortem brain and biofluids in AD patients compared to the healthy population.	3	Zainuddin Muhammad-Safuan (2026)	Oxidative stress biomarkers and flavonoids in Alzheimer's disease: current clinical evidence and therapeutic perspectives
Cacao Flavanol Cognitive Performance Randomized Trial	1 1 2 1 3 4 5 Alzheimer's disease (AD) is the most prominent age-related neurodegenerative disease in the world [].	3	Zainuddin Muhammad-Safuan (2026)	Oxidative stress biomarkers and flavonoids in Alzheimer's disease: current clinical evidence and therapeutic perspectives
Cacao Flavanol Cognitive Performance Randomized Trial	MetS is a multifactorial condition, with its primary indicators including obesity, hypertension, dyslipidemia, insulin resistance, and hyperglycemia; i.e., a patient who possesses at least 3 of the following parameters is designated with MetS: glucose intolerance, increased levels of triglycerides, augmented waist circumference, low levels of high-density lipoprotein cholesterol (HDL-c), and hypertension [,,].	3	Tomaru Júlia Mayumi (2026)	Beyond Taste: The Impact of Chocolate on Cardiovascular and Steatotic Liver Disease Risk Factors
Cacao Flavanol Cognitive Performance Randomized Trial	It is possible to develop a close relationship with MetS, metabolic dysfunction-associated steatotic liver disease (MASLD), and CVD [,].	3	Tomaru Júlia Mayumi (2026)	Beyond Taste: The Impact of Chocolate on Cardiovascular and Steatotic Liver Disease Risk Factors
Cacao Flavanol Cognitive Performance Randomized Trial	MASLD is strongly associated with various conditions, including MetS, and is characterized by the persistence of a chronic inflammatory state detrimental to the organism [,].	3	Tomaru Júlia Mayumi (2026)	Beyond Taste: The Impact of Chocolate on Cardiovascular and Steatotic Liver Disease Risk Factors
Cacao Flavanol Cognitive Performance Randomized Trial	1 2 3 4 5 6 7 8 9 10 11 12 13 14 Metabolic disorders are increasing sharply due to severe modifications in lifestyle [,,,].	3	Tomaru Júlia Mayumi (2026)	Beyond Taste: The Impact of Chocolate on Cardiovascular and Steatotic Liver Disease Risk Factors